Anti-telomerase cancer therapy: Cancer suppressor VHL (Von Hippel-Lindau) suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of it target gene, 10/December/2016, 11.53 am

Natural product-derived therapy for overcoming chemoresistance in Human cancers: Amla extract increases the expression of CADM1, decreases BMI1 translocation, increases tumor suppressor INK4a/p16 expression and restores chemosensitivity in drug-resistant Human cancers via down regulation of its target gene, 10/December/2016, 8.51 am
December 10, 2016
Natural product-derived PD-1 pathway blockade for Human cancer therapy: Moringa Olifera extract decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 10/December/2016, 6.34 pm
December 10, 2016
Show all

Introduction: What they say:  

The 1989 Nobel prize winner in Chemistry, Prof. Thomas R. Cech from the BioFrontiers Institute, USA has published a research paper in the 13 December 2012 Nature (492(7428):285-9; and I.F: >42) stating that “The TEL patch of telomere protein TPP1 mediates telomerase recruitment and processivity.”  This study provides mechanistic insights into how TPP1 regulates telomerase function.


What we say

In connection with this finding,  Dr Boominathan, Founder Director-cum-chief scientist of GBMD, reports, for the first time, that: Cancer suppressor VHL (Von Hippel-Lindau) suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and the cellular immortality gene telomerase and inhibits cancer progression via down-regulation of it target gene


Significance of the study:

Given that: (1) over 90% human tumors overexpress immortality gene telomerase; and (2) cancer causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) a way to inhibit telomerase activity in human tumors; (ii) a way to increase the efficacy of anticancer therapy;  (iii) a cheaper alternative to the existing expensive drugs; (iv) a side-effect-free natural product-based drug; (v) a way to effectively treat cancers that are resistant to anticancer drugs;  (vi) a way to prevent tumor recurrence; and (vii) a way to effectively treat and eradicate metastatic progression of cancer.


From Research Findings to Therapeutic opportunity:

vhl-suppresses-tpp1-and-telomerase-expression1

Figure1. VHL suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and the cellular immortality gene telomerase. Thereby, it inhibits cancer proliferation via down regulation of its target genes

This study suggests that tumor suppressor VHL, by increasing the expression of its target gene, it may suppress the expression of Tripeptidyl Peptidase 1 (TPP1) and Telomerase (Fig 1). Remarkably, over 90% of the human tumors overexpress the cellular immortality gene telomerase, suggesting that inhibition of its activity may increase the efficacy of anticancer therapy. 

Taken together, pharmacological formulations encompassing “VHL   activators or  VHL   activators in combination with other anti-cancer drugs may be used to treat human cancers that specifically overexpress the cellular immortality gene telomerase. 

price-100

[easy_payment currency=”USD”]


Details of the Research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $100#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed information: How VHL  suppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and telomerase?
For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

CitationBoominathan, L., Anti-telomerase cancer therapy: Cancer suppressor VHL (Von Hippel-Lindausuppresses the expression of Tripeptidyl Peptidase 1 (TPP1) and inhibits cancer progression via down-regulation of it target gene, 10/December/2016, 11.53 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Comments are closed.